2016 International Congress

Thursday, June 23, 2016

12:00pm-1:30pm

Neuroprotection effect of an endogenous amine, 1MeTIQ against disturbances in dopamine release induced by the neurotoxin, 6-OHDA: In vivo microdialysis study

A. Wasik, I. Romanska, L. Antkiewicz-Michaluk (Krakow, Poland)

Neuropharmacology  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Neuroprotective and antidepressant-like effects of the endogenous amines from tetrahydroisoquinoline group TIQ and 1MeTIQ in the animal model of depressive disorder: Behavioral and neurochemical studies in the rat

L.R. Antkiewicz-Michaluk (Krakow, Poland)

Neuropharmacology  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

New therapeutic algorithm for abnormal posture in Parkinson’s disease and related disorders

Y. Mukai, Y. Furusawa, Y. Aoshima, H. Todo, Y. Hama, C. Matsumoto, N. Wakasugi, Y. Mizuno, T. Kawazoe, Y. Saitoh, T. Sakamoto, M. Murata (Tokyo, Japan)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Nilotinib improves motor skills, cognition and autonomic function in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia

F. Pagan, E. Valadez, Y. Torres-Yaghi, A. Keys, R. Falconer, S. Rogers, B. Wilmarth, M. Hebron, C. Moussa (Washington, DC, USA)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Nilotinib significantly alters CSF biomarkers and increases endogenous dopamine in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia

C. Moussa, E. Valadez, Y. Torres-Yaghi, A. Keys, R. Falconer, S. Rogers, B. Wilmarth, M. Hebron, F. Pagan (Washington, DC, USA)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Non-motor symptoms evaluation in idiopathic cervical dystonia

N. Novaretti, V. Tumas (Ribeirão Preto, Brazil)

Dystonia  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Novel mutations identified in dopamine transporter deficiency syndrome

J. Ng, J. Zhen, K. Erreger, N.C. Oien, S. Mohammed, J.P. Linn, J. Muntadas, I. Denzler, A. Garcia Cazorla, R. Artuch, S. Pope, S.J.R. Heales, A. Galli, M.E.A. Reith, M.A. Kurian (London, United Kingdom)

Pediatric movement disorder  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Novel small molecules targeting alpha-synuclein aggregation for the treatment of Parkinson’s disease

E. Tsika, A. Davranche, E. Gabellieri, S. Nampally, J. Molette, S. Papin, H. Kroth, A. Pfeifer, D. Lowe, A. Muhs (Lausanne, Switzerland)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Novel training based on declarative memory cues improves gait perfromance in patients with Parkinson’s disease: A randomized clinical trial

M.E.P. Piemonte, E. Okamoto, K.R. Cardoso, T.P. Oliveira, C.S. Miranda, M. Pikel, F. Mendes, G.F. Xavier (Sao Paulo, Brazil)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Nursing diagnoses and interventions in rehabilitation related to antiParkinsonian pharmacotherapy

M.H.S. Tosin, B.G.R.B. Oliveira, T.R. Garcia (Rio de Janeiro, Brazil)

Other  ·  Exhibit Hall located in Hall B, Level 2